Vasicine (VAS), a potential natural cholinesterase inhibitor, exhibited promising anticholinesterase activity in preclinical models and has been in development for treatment of Alzheimer’s disease. Here, BCHE is linked to early-onset autosomal dominant Alzheimer disease.